The hypothalamic glucagon-like peptide 1 receptor Is sufficient but not necessary for the regulation of energy balance and glucose homeostasis in mice
A Monarch physician reviews your X-ray during your visit, and a radiologist's final read follows after the visit, and timing may vary
In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids
The SURMOUNT-1 trial (N=2,539) reported a vomiting rate of 12.2% for tirzepatide 15 mg, lower than the 24.8% seen with semaglutide 2.4 mg in STEP 1, although cross-trial comparisons have significant limitations [16]
And, although relatively rare, some people can develop pancreatitis, or inflammation of the pancreas